Within this declining effector T-cell pool, CCR6+ cells co-expressed CCR4 (subclusters 7.1 and 7.2) or CXCR3 (subclusters 7.3 and 7.4), indicating that levels of both Th17- and Th1-like Th17 cells may be reduced by tolDC therapy, both of which have been proposed to associate with beta-cell destruction and T1D (32–36). The gene discussed is CXCR3; the disease is type 1 diabetes mellitus.